Gemcitabine-induced thrombotic microangiopathy.

Abstract

Thrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterised by platelet aggregation, thrombocytopenia and end-organ damage. It is commonly idiopathic, although several drug classes, including cytotoxic chemotherapy, have been implicated. Several of cases of gemcitabine-induced TMA have been documented with incidence likely to increase with the escalating use of gemcitabine. We report the cases of two patients who developed TMA while on gemcitabine chemotherapy.

• Authors: J Richmond, P Gilbar, E Abro
• Journal: Internal medicine journal (Intern Med J) Vol. 43 Issue 11 Pg. 1240-2 (Nov 2013) ISSN: 1445-5994 [Electronic] Australia
• PMID: 24237646 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 The Authors; Internal Medicine Journal © 2013 Royal Australasian College of Physicians.

Chemical References

• Antimetabolites, Antineoplastic
• Deoxycytidine
• Gemcitabine

Topics

• Aged
• Antimetabolites, Antineoplastic (adverse effects)
• Deoxycytidine (adverse effects, analogs & derivatives)
• Female
• Humans
• Male
• Middle Aged
• Thrombotic Microangiopathies (chemically induced, diagnosis)
• Gemcitabine